{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:45:22Z","timestamp":1792129522694,"version":"4.4.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.seminhematol.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:43:48Z","timestamp":1784331828000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting"],"prefix":"10.1053","volume":"63","author":[{"given":"Khaled","family":"Elhusseiny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2106-3698","authenticated-orcid":false,"given":"Brandi N.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2026.07.001_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106809","article-title":"Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia","volume":"115","author":"Pemmaraju","year":"2022","journal-title":"Leuk Res"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.001_bib0003","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040620716680333","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease","volume":"8","author":"How","year":"2017","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-023-00972-x","article-title":"One thousand patients with essential thrombocythemia: the Mayo Clinic experience","volume":"14","author":"Gangat","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-023-00968-7","article-title":"One thousand patients with essential thrombocythemia: the Florence-CRIMM experience","volume":"14","author":"Loscocco","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.001_bib0006","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/ejh.70008","article-title":"Patient characteristics, healthcare contacts and drug use in polycythaemia vera in Denmark","volume":"115","author":"Lundgaard","year":"2025","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0007","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.kint.2023.09.010","article-title":"The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms","volume":"104","author":"d'Izarny-Gargas","year":"2023","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0008","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0009","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ejh.13721","article-title":"Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): a retrospective single-center study of 829 MPN patients","volume":"108","author":"Wille","year":"2022","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0010","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/bloodadvances.2025016247","article-title":"Thrombosis, major bleeding, and mortality in 1079 patients with myelofibrosis: a matched population-based study","volume":"9","author":"Enblom Larsson","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.07.001_bib0011","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1055\/a-1849-8477","article-title":"Hemorrhages in polycythemia vera and essential thrombocythemia: epidemiology, description, and risk factors-learnings from a large cohort","volume":"122","author":"Nicol","year":"2022","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-023-00972-x","article-title":"One thousand patients with essential thrombocythemia: the Mayo Clinic experience","volume":"14","author":"Gangat","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0014","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41408-023-00960-1","article-title":"The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients","volume":"13","author":"Barbui","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41408-024-01169-6","article-title":"Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors","volume":"14","author":"Barbui","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0016","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","article-title":"Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche","volume":"1","author":"Yoshihara","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0017","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.V86.2.419.bloodjournal862419","article-title":"Thrombopoietin: the primary regulator of platelet production","volume":"86","author":"Kaushansky","year":"1995","journal-title":"Blood"},{"issue":"6481","key":"10.1053\/j.seminhematol.2026.07.001_bib0018","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/369565a0","article-title":"Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo","volume":"369","author":"Lok","year":"1994","journal-title":"Nature"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0019","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood.V87.6.2154.bloodjournal8762154","article-title":"Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets","volume":"87","author":"Fielder","year":"1996","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.stem.2007.10.008","article-title":"Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells","volume":"1","author":"Qian","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0021","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199809103391107","article-title":"Thrombopoietin","volume":"339","author":"Kaushansky","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.001_bib0022","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood.V89.3.883","article-title":"Thrombopoietin enhances the \u03b1IIb\u03b23-dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase","volume":"89","author":"Zauli","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0023","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/blood-2008-06-162032","article-title":"Group IVA cytosolic phospholipase A2 (cPLA2\u03b1) and integrin \u03b1IIb\u03b23 reinforce each other's functions during \u03b1IIb\u03b23 signaling in platelets","volume":"113","author":"Pr\u00e9vost","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0024","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1182\/blood.V87.11.4664.bloodjournal87114664","article-title":"Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists","volume":"87","author":"Oda","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2008.01.001","article-title":"Thromboxane A2: physiology\/pathophysiology, cellular signal transduction and pharmacology","volume":"118","author":"Nakahata","year":"2008","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.001_bib0026","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1055\/s-0037-1613872","article-title":"Thrombopoietin increases platelet sensitivity to alpha-thrombin via activation of the ERK2-cPLA2 pathway","volume":"83","author":"van Willigen","year":"2000","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0027","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000578","article-title":"Functional consequences of mutations in myeloproliferative neoplasms","volume":"5","author":"Constantinescu","year":"2021","journal-title":"Hemasphere"},{"issue":"52","key":"10.1053\/j.seminhematol.2026.07.001_bib0028","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.001_bib0029","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its Mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0030","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41467-023-37277-3","article-title":"Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation","volume":"14","author":"Papadopoulos","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.001_bib0031","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2025.287585","article-title":"Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL","volume":"111","author":"Masubuchi","year":"2026","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.001_bib0032","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2005-06-2600","article-title":"An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor","volume":"107","author":"Staerk","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232801","article-title":"Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera","volume":"15","author":"Spivak","year":"2020","journal-title":"PLoS One"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.07.001_bib0035","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2014-07-587238","article-title":"The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm","volume":"124","author":"Sangkhae","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.001_bib0036","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.2025029479","article-title":"Dissecting JAK2V617F\u2019s double life with and without MPL","volume":"146","author":"Plo","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.001_bib0037","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/blood.2024026711","article-title":"Delineating mpl-dependent and -independent phenotypes of Jak2 V617F-positive MPNs in vivo","volume":"146","author":"Papadopoulos","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.001_bib0038","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/leu.2016.308","article-title":"Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib","volume":"31","author":"Shide","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.001_bib0039","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199802263380903","article-title":"Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera","volume":"338","author":"Moliterno","year":"1998","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.07.001_bib0040","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1182\/blood-2012-03-417261","article-title":"JAK2 V617F down-modulates MPL","volume":"119","author":"Fleischman","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.07.001_bib0041","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1182\/blood-2011-08-372524","article-title":"Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes","volume":"119","author":"Pecquet","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.07.001_bib0042","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","article-title":"Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression","volume":"108","author":"Moliterno","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.07.001_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.641613","article-title":"The thrombopoietin receptor, MPL, is a therapeutic target of opportunity in the MPN","volume":"11","author":"Spivak","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.001_bib0044","first-page":"312","article-title":"Pujol-Moix N. Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels","volume":"84","author":"Espa\u00f1ol","year":"1999","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden","volume":"84","author":"Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol"},{"issue":"2\u20133","key":"10.1053\/j.seminhematol.2026.07.001_bib0046","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0049-3848(02)00354-7","article-title":"Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes","volume":"108","author":"Villmow","year":"2002","journal-title":"Thromb Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0047","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1365-2141.2000.02030.x","article-title":"Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders","volume":"110","author":"Jensen","year":"2000","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.001_bib0048","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","article-title":"Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera","volume":"33","author":"Falanga","year":"2005","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.001_bib0049","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/095371000403134","article-title":"Increased leukocyte-platelet adhesion in chronic myeloproliferative disorders with high platelet counts","volume":"11","author":"Kaplar","year":"2000","journal-title":"Platelets"},{"key":"10.1053\/j.seminhematol.2026.07.001_bib0050","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3389\/fimmu.2019.01373","article-title":"Platelets as mediators of thromboinflammation in chronic myeloproliferative neoplasms","volume":"10","author":"Marin Oyarz\u00fan","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0051","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/ijlh.13754","article-title":"Correlation between leukocyte-platelet aggregates and thrombosis in myeloproliferative neoplasms","volume":"44","author":"\u0160efer","year":"2022","journal-title":"Int J Laborat Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.07.001_bib0052","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1161\/ATVBAHA.110.216143","article-title":"Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2\/Rac1\/p38 mitogen-activated protein kinase signaling pathway","volume":"30","author":"Yacoub","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.seminhematol.2026.07.001_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.825892","article-title":"Platelets as key factors in inflammation: focus on CD40L\/CD40","volume":"13","author":"Cognasse","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.07.001_bib0054","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacc.2009.03.076","article-title":"The CD40\/CD40 ligand system: linking inflammation with atherothrombosis","volume":"54","author":"Antoniades","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.001_bib0055","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1055\/s-0038-1649916","article-title":"Increased thromboxane biosynthesis in essential thrombocythemia","volume":"74","author":"Rocca","year":"1995","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.07.001_bib0056","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","article-title":"Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo","volume":"80","author":"Landolfi","year":"1992","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.07.001_bib0057","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.001_bib0058","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3324\/haematol.2022.282136","article-title":"The relative importance of platelet integrins in hemostasis, thrombosis and beyond","volume":"108","author":"Janus-Bell","year":"2023","journal-title":"Haematologica"},{"issue":"Suppl-1","key":"10.1053\/j.seminhematol.2026.07.001_bib0059","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1538-7836.2009.03378.x","article-title":"The structure and function of platelet integrins","volume":"7","author":"Bennett","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0060","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/bjh.16335","article-title":"Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?","volume":"189","author":"Lucchesi","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.001_bib0061","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood-2012-05-431288","article-title":"Dysfunction of the PI3 kinase\/Rap1\/integrin \u03b1(IIb)\u03b2(3) pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia","volume":"121","author":"Moore","year":"2013","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.07.001_bib0062","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2025-415","article-title":"Platelet priming in MPN triggers pro-thrombotic intermediate affinity state in \u03b1IIb\u03b23 integrin","volume":"146","author":"Martianov","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0063","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3892\/ol.2017.6459","article-title":"Clinical significance of circulating microparticles in ph(-) myeloproliferative neoplasms","volume":"14","author":"Zhang","year":"2017","journal-title":"Oncol Lett"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.001_bib0064","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/09537104.2019.1639655","article-title":"Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists","volume":"31","author":"Garabet","year":"2020","journal-title":"Platelets"},{"key":"10.1053\/j.seminhematol.2026.07.001_bib0065","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fphar.2016.00314","article-title":"Antiplatelet agents inhibit the generation of platelet-derived microparticles","volume":"7","author":"Giacomazzi","year":"2016","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.001_bib0066","doi-asserted-by":"crossref","first-page":"e172256","DOI":"10.1172\/JCI172256","article-title":"Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms","volume":"134","author":"He","year":"2024","journal-title":"J Clin Invest"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.07.001_bib0067","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood.2023022260","article-title":"Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"45","key":"10.1053\/j.seminhematol.2026.07.001_bib0068","doi-asserted-by":"crossref","first-page":"16900","DOI":"10.1073\/pnas.0608207103","article-title":"The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis","volume":"103","author":"Bergmeier","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0069","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00018-014-1743-8","article-title":"Of von Willebrand factor and platelets","volume":"72","author":"Bryckaert","year":"2015","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.001_bib0070","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/jth.15717","article-title":"Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia","volume":"20","author":"Kubo","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.001_bib0071","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1046\/j.1365-2141.2003.04292.x","article-title":"Thrombopoietin increases platelet adhesion under flow and decreases rolling","volume":"121","author":"Van Os","year":"2003","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.001_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102954","article-title":"Thrombocytosis and bleeding in myeloproliferative neoplasms: exploring clinical diversity and risk of acquired von Willebrand syndrome-insights from a UK center","volume":"9","author":"Simini","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.07.001_bib0073","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1007\/s00277-025-06648-9","article-title":"Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms","volume":"104","author":"Gat","year":"2025","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0074","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2006-949664","article-title":"The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.07.001_bib0075","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1161\/ATVBAHA.120.314760","article-title":"Platelet dysfunction and thrombosis in JAK2(V617F)-mutated primary myelofibrotic mice","volume":"40","author":"Matsuura","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0076","first-page":"894","article-title":"Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders","volume":"103","author":"Malpass","year":"1984","journal-title":"J Lab Clin Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0077","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0038-1657135","article-title":"Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders","volume":"47","author":"Pareti","year":"1982","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100060","article-title":"Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2 (V617F) mutation","volume":"7","author":"Guy","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0079","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000207311","article-title":"Chronic myeloproliferative disorders: a quantitative assessment of platelet ultrastructure","volume":"64","author":"Boughton","year":"2009","journal-title":"Acta Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12185-013-1475-9","article-title":"JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients","volume":"99","author":"Coucelo","year":"2014","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0081","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ajcp\/91.6.647","article-title":"Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome, and secondary thrombocytosis","volume":"91","author":"Raman","year":"1989","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0082","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1172\/JCI122955","article-title":"Functional significance of the platelet immune receptors GPVI and CLEC-2","volume":"129","author":"Rayes","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0083","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1161\/ATVBAHA.121.316108","article-title":"Platelet GPVI (Glycoprotein VI) and thrombotic complications in the venous system","volume":"41","author":"Perrella","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.07.001_bib0084","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/ajh.70066","article-title":"GPVI as a potential new biomarker for myelofibrosis diagnosis","volume":"100","author":"Hittinger","year":"2025","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.07.001_bib0085","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3324\/haematol.2022.280838","article-title":"Is it primary myelofibrosis or chronic megakaryocytic leukemia?","volume":"107","author":"Lichtman","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.07.001_bib0086","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","article-title":"Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice","volume":"100","author":"Chagraoui","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0087","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1182\/blood.V86.11.4025.bloodjournal86114025","article-title":"Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice","volume":"86","author":"Yan","year":"1995","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0088","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood.V90.11.4369","article-title":"High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice","volume":"90","author":"Villeval","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.001_bib0089","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2002-06-1913","article-title":"Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice)","volume":"100","author":"Vannucchi","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.001_bib0090","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41375-024-02354-z","article-title":"Proteomic screening identifies PF4\/Cxcl4 as a critical driver of myelofibrosis","volume":"38","author":"Capitanio","year":"2024","journal-title":"Leukemia"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.07.001_bib0091","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.2019004095","article-title":"Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN","volume":"136","author":"Gleitz","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.001_bib0092","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.1991.tb07952.x","article-title":"Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia","volume":"77","author":"Martyr\u00e9","year":"1991","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.07.001_bib0093","doi-asserted-by":"crossref","first-page":"qiaf093","DOI":"10.1093\/jleuko\/qiaf093","article-title":"Megakaryocyte emperipolesis in myeloproliferative neoplasms: are neutrophils friends or foes?","volume":"117","author":"Collinson","year":"2025","journal-title":"J Leukocyte Biol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0094","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood.2024027455","article-title":"Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24","volume":"146","author":"Khatib-Massalha","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.07.001_bib0095","first-page":"2832","article-title":"Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2","volume":"118","author":"Bersenev","year":"2008","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0096","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood-2014-07-588145","article-title":"MERIT40 deficiency expands hematopoietic stem cell pools by regulating thrombopoietin receptor signaling","volume":"125","author":"Rozenova","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0097","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.3707","article-title":"Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion","volume":"20","author":"Bruns","year":"2014","journal-title":"Nat Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0098","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm.3706","article-title":"Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells","volume":"20","author":"Zhao","year":"2014","journal-title":"Nat Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0099","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/stem.2888","article-title":"JAK2V617F Megakaryocytes promote hematopoietic stem\/progenitor cell expansion in mice through thrombopoietin\/MPL signaling","volume":"36","author":"Zhang","year":"2018","journal-title":"Stem Cells"},{"issue":"7414","key":"10.1053\/j.seminhematol.2026.07.001_bib0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.001_bib0101","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70137","article-title":"Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea\/best available therapy (PROUD-PV\/CONTINUATION-PV)","volume":"9","author":"Kiladjian","year":"2025","journal-title":"Hemasphere"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.001_bib0102","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.07.001_bib0103","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.07.001_bib0104","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2021010986","article-title":"Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms","volume":"138","author":"Mosca","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0105","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","article-title":"Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1","volume":"96","author":"Wang","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.001_bib0106","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"J Cell Mol Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.001_bib0107","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/bloodadvances.2023011620","article-title":"Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results","volume":"8","author":"Yacoub","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.001_bib0108","doi-asserted-by":"crossref","first-page":"oyag201","DOI":"10.1093\/oncolo\/oyag201","article-title":"Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study","volume":"31","author":"Kiladjian","year":"2026","journal-title":"Oncologist"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.07.001_bib0109","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2015-10-674465","article-title":"A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.07.001_bib0110","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1182\/blood.2024024636","article-title":"cMPL-based purification and depletion of human hematopoietic stem cells: implications for pretransplant conditioning","volume":"145","author":"Araki","year":"2025","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.07.001_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.07.037","article-title":"Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis","volume":"186","author":"Tsutsumi","year":"2023","journal-title":"Cell"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.001_bib0112","first-page":"1000018","article-title":"Structural basis of MPL activation by thrombopoietin","volume":"1","author":"Mafi","year":"2024","journal-title":"Blood Vessels Thrombos Hemostas"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.001_bib0113","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1096\/fj.10-178673","article-title":"Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation","volume":"25","author":"Matthews","year":"2011","journal-title":"Faseb J"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.07.001_bib0114","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood.2024024373","article-title":"Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN","volume":"144","author":"Reis","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.07.001_bib0115","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood-2025-1024","article-title":"Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia","volume":"146","author":"Gupta","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.07.001_bib0116","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood-2025-484","article-title":"Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): preliminary results from dose escalation of two global phase 1 studies","volume":"146","author":"Mascarenhas","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.07.001_bib0117","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2023-173430","article-title":"Discovery of JNJ-88549968, a novel, first-in-class CALRmutxCD3 T-cell redirecting antibody for the treatment of myeloproliferative neoplasms","volume":"142","author":"Kuchnio","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.07.001_bib0118","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1182\/blood.2024027897","article-title":"Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity","volume":"147","author":"Thompson-Peach","year":"2026","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.07.001_bib0119","series-title":"30th Congress of the European Hematology Association 2025","article-title":"INCA035784, a novel, equipotent T cell-redirecting antibody for patients with myeloproliferative neoplasms carrying different types of calreticulin mutations","author":"Pandey","year":"2025"},{"issue":"856","key":"10.1053\/j.seminhematol.2026.07.001_bib0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adz3553","article-title":"CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis","volume":"18","author":"Rampotas","year":"2026","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.001_bib0121","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2017849118","article-title":"Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors","volume":"118","author":"Cui","year":"2021","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:58:55Z","timestamp":1792126735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0037196326000703"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.07.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}